DAFNA Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

DAFNA Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-229,652	Closed	-$9.85M	–	76
2020 Q3	$9.85M	Buy	229,652 +80,635	+54%	+$4M	3.2%	5
2020 Q2	$6.96M	Buy	149,017 +96,431	+183%	+$3.32M	2.01%	13
2020 Q1	$715K	Sell	52,586 -121,328	-70%	-$1.55M	0.3%	59
2019 Q4	$1.89M	Hold	173,914	–	–	0.65%	35
2019 Q3	$1.79M	Buy	173,914 +171,514	+7,146%	+$1.85M	0.67%	38
2019 Q2	$23K	Sell	2,400 -44,855	-95%	-$329K	0.01%	87
2019 Q1	$323K	Sell	47,255 -25,550	-35%	-$131K	0.14%	71
2018 Q4	$330K	Buy	+72,805	New	+$448K	0.16%	67
2014 Q3	–	Sell	-12,142	Closed	-$1.47M	–	60
2014 Q2	$1.47M	Buy	12,142 +10,768	+784%	+$1.3M	1.39%	18
2014 Q1	$175K	Buy	+1,374	New	+$204K	0.15%	45

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

DAFNA Capital Management's ARCT Position: Q4 2020 in Review

DAFNA Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2020, closing a stake of 229,652 shares — an estimated $9.85M sold.

DAFNA Capital Management first reported a position in ARCT in Q1 2014 and held it in 10 quarters. The position peaked at $9.85M in Q3 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q4 2020.

DAFNA Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2020 after selling out during the quarter.
DAFNA Capital Management sold 229,652 Arcturus Therapeutics shares in Q4 2020, an estimated $9.85M.
DAFNA Capital Management first reported a position in Arcturus Therapeutics in Q1 2014 and held it in 10 quarters.
DAFNA Capital Management's Arcturus Therapeutics position peaked at $9.85M in Q3 2020.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2020.

Based on DAFNA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.